Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All remdesivir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 0% Improvement Relative Risk Mortality, day 60 -36% Mortality, day 28 55% Remdesivir  Barrat-Due et al.  LATE TREATMENT  DB RCT Is late treatment with remdesivir beneficial for COVID-19? Double-blind RCT 99 patients in Norway Trial underpowered to detect differences c19early.org Barrat-Due et al., Annals of Internal .., Jul 2021 Favors remdesivir Favors control

Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19

Barrat-Due et al., Annals of Internal Medicine, doi:10.7326/M21-0653, NCT04321616
Jul 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Small RCT in Norway with 52 HCQ and 42 remdesivir patients, showing no significant differences with treatment. Add-on trial to WHO Solidarity. NCT04321616 (history).
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
Study covers remdesivir and HCQ.
risk of death, no change, RR 1.00, p = 1.00, treatment 3 of 42 (7.1%), control 4 of 57 (7.0%), adjusted per study.
risk of death, 35.7% higher, RR 1.36, p = 0.70, treatment 3 of 42 (7.1%), control 3 of 57 (5.3%), day 60.
risk of death, 54.8% lower, RR 0.45, p = 0.63, treatment 1 of 42 (2.4%), control 3 of 57 (5.3%), NNT 35, day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Barrat-Due et al., 13 Jul 2021, Double Blind Randomized Controlled Trial, Norway, peer-reviewed, 41 authors, average treatment delay 8.0 days, trial NCT04321616 (history).
This PaperRemdesivirAll
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19
PhD; Andreas Barratt-Due, PhD Inge Christoffer Olsen, PhD Katerina Nezvalova-Henriksen, MD Trine Kåsine, PhD Fridtjof Lund-Johansen, PhD Hedda Hoel, Aleksander Rygh Holten, PhD; Anders Tveita, PhD Alexander Mathiessen, MD Mette Haugli, MD Ragnhild Eiken, PhD Anders Benjamin Kildal, PhD Åse Berg, PhD Asgeir Johannessen, PhD Lars Heggelund, Tuva Børresdatter Dahl, MSc Karoline Hansen Skåra, MD; Pawel Mielnik, Lan Ai Kieu Le, MD Lars Thoresen, MD; Dag Gernot Ernst, Dag Arne Lihaug Hoff, MD; Bård Hilde Skudal, Bård Reiakvam Kittang, Roy Bjørkholt Olsen, MD; Carl Birgitte Tholin, Carl Magnus Ystrøm, MD Nina Vibeche Skei, PhD Trung Tran, PhD Susanne Dudman, PhD Jan Terje Andersen, MD Raisa Hannula, PhD; Olav Dalgard, PhD Ane-Kristine Finbråten, PhD Kristian Tonby, PhD; Bjorn Blomberg, MD Saad Aballi, PhD Cathrine Fladeby, MSc Anne Steffensen, PhD Fredrik Müller, PhD Anne Ma Dyrhol-Riise, PhD Marius Trøseid, PhD Pål Aukrust
Annals of Internal Medicine, doi:10.7326/m21-0653
Background: New treatment modalities are urgently needed for patients with COVID-19. The World Health Organization (WHO) Solidarity trial showed no effect of remdesivir or hydroxychloroquine (HCQ) on mortality, but the antiviral effects of these drugs are not known. Objective: To evaluate the effects of remdesivir and HCQ on all-cause, in-hospital mortality; the degree of respiratory failure and inflammation; and viral clearance in the oropharynx. Design: NOR-Solidarity is an independent, add-on, randomized controlled trial to the WHO Solidarity trial that included biobanking and 3 months of clinical follow-up (ClinicalTrials. gov: NCT04321616) Setting: 23 hospitals in Norway. Patients: Eligible patients were adults hospitalized with confirmed SARS-CoV-2 infection. Intervention: Between 28 March and 4 October 2020, a total of 185 patients were randomly assigned and 181 were included in the full analysis set. Patients received remdesivir (n = 42), HCQ (n = 52), or standard of care (SoC) (n = 87). Measurements: In addition to the primary end point of WHO Solidarity, study-specific outcomes were viral clearance in oropharyngeal specimens, the degree of respiratory failure, and inflammatory variables. Results: No significant differences were seen between treatment groups in mortality during hospitalization. There was a marked decrease in SARS-CoV-2 load in the oropharynx during the first week overall, with similar decreases and 10-day viral loads among the remdesivir, HCQ, and SoC groups. Remdesivir and HCQ did not affect the degree of respiratory failure or inflammatory variables in plasma or serum. The lack of antiviral effect was not associated with symptom duration, level of viral load, degree of inflammation, or presence of antibodies against SARS-CoV-2 at hospital admittance. Limitation: The trial had no placebo group. Conclusion: Neither remdesivir nor HCQ affected viral clearance in hospitalized patients with COVID-19.
EDTA plasma samples were taken at randomization, between days 3 and 5, between days 7 and 9, and weekly thereafter. CRP, ferritin, procalcitonin, LDH, lymphocytes, and neutrophils were analyzed by the routine laboratory at the hospitals included in the study. Treatment effects are given as estimated differences in daily decrease rates (slopes) of the variables between remdesivir and its SoC during the first week, and in differences in point estimates at day 10. Results are presented as estimated treatment differences with 95% CIs. CRP = C-reactive protein; LDH = lactate dehydrogenase; SoC = standard of care. * To convert to SI units (mkat/L), multiply by 0.0167. EDTA plasma samples were taken at randomization, between days 3 and 5, between days 7 and 9, and weekly thereafter. CRP, ferritin, procalcitonin, LDH, lymphocytes, and neutrophils were analyzed by the routine laboratory at the hospitals included in the study. Treatment effects are given as estimated differences in daily decrease rates (slopes) of the variables between HCQ and its SoC during the first week, and in differences in point estimates at day 10. Results are presented as estimated treatment differences with 95% CIs. CRP = C-reactive protein; HCQ = hydroxychloroquine; LDH = lactate dehydrogenase; SoC = standard of care. * To convert to SI units (mkat/L), multiply by 0.0167. Subgroup analyses evaluating the effect on viral clearance of remdesivir compared with SoC in patients with short (<7 d) and long (≥7 d)..
References
Amanat, Stadlbauer, Strohmeier, A serological assay to detect SARS-CoV-2 seroconversion in humans, Nat Med, doi:10.1038/s41591-020-0913-5
Beigel, Tomashek, Dodd, ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 -final report, N Engl J Med, doi:10.1056/NEJMoa2007764
Bergen, Dr ; Grålum, Johannessen, Mielnik, Olsen et al., Critical revision of the article for important intellectual content: A
Bimonte, Crispo, Amore, Potential antiviral drugs for SARS-cov-2 treatment: preclinical findings and ongoing clinical research, Vivo, doi:10.21873/invivo.11949
Dolin, Hirsch, Remdesivir-an important first step
Dr, Berg, None
Dr, Blomberg, None, Jonas Lies veg
Dr, Haugli, None, Postboks
Dr, Johannessen, None
Dr, Mathiessen, None
Dr, None
Dr, None, Finbråten: Lovisenberg Diaconal Hospital, Lovisenberggata
Dr, Tholin: Molde Hospital, Parkvegen 84 6412
Dreier, Störmer, Kleesiek, Use of bacteriophage MS2 as an internal control in viral reverse transcription-PCR assays, J Clin Microbiol, doi:10.2807/1560-7917.ES.2020.25.3.2000045
Drs, Barratt-Due, Olsen, Nezvalova-Henriksen, Lund-Johansen et al., Current Author Addresses
Elverum, Dr, Skei, Trøndelag Hospital Trust/NTNU, Postboks
Førde, Hospital, Førde, Norway, None
Gordon, Winer, Hoogendijk, Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis, Cochrane Database Syst Rev, doi:10.1002/14651858.CD003643.pub4
Haugesund, Dr, Thoresen, None, Arnhold Dybjords vei
Holter, Pischke, De Boer, Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients, Proc Natl Acad Sci U S A, doi:10.1073/pnas.2010540117
Horby, Mafham, Linsell, Effect of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med, doi:10.1056/NEJMoa2022926
Hospital, None
Hospital, None
Hospital, Viken, Trust, None
Hønefoss, Dr, Hoff, None
Investigators, Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, JAMA, doi:10.1001/jama.2020.16349
Kristiansand, Dr, Eiken, None, Innlandet Hospital Trust Anders Sandvigs Gate
Laake, Buanes, Småstuen, Characteristics, management and survival of ICU patients with coronavirus disease-19 in Norway, March-June 2020. A prospective observational study, Acta Anaesthesiol Scand, doi:10.1111/aas.13785
Levanger, Dr, Hannula, None
Lyngbakken, Berdal, Eskesen, A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics, Nat Commun, doi:10.1038/s41467-020-19056-6
Maciorowski, Idrissi, Gupta, A review of the preclinical and clinical efficacy of remdesivir, hydroxychloroquine, and lopinavir-ritonavir treatments against COVID-19, SLAS Discov, doi:10.1177/247255522095838516
Nydalen, None
Oslo, Dr, Mielnik, Helse Førde, Svanehaugvegen 2
Oslo, Drs, Tveita, None, Postboks
Pan, Peto, Henao-Restrepo, WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19-interim WHO Solidarity trial results, N Engl J Med, doi:10.1056/NEJMoa2023184
Rochwerg, Siemieniuk, Agoritsas, A living WHO guideline on drugs for covid-19, BMJ, doi:10.1136/bmj.m3379
Skien, Dr, Kittang, Haraldsplass Deaconess Hospital
Spinner, Gottlieb, Criner, None
Torgarden, None
Tønsberg, Dr, Dahl, None
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV)
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit